Leap Therapeutics (FRA:5MC) Net Income (Continuing Operations) : €-64.09 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Leap Therapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was €-14.28 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was €-64.09 Mil.

Leap Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Leap Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Net Income (Continuing Operations) Chart

Leap Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-22.62

-35.92

-51.54

-74.66

-64.52

Leap Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-12.71	-18.70	-16.38	-14.74	-14.28

Leap Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-64.09 Mil.

Leap Therapeutics (FRA:5MC) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Leap Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Headlines

No Headlines